Abstract:Background: Acute kidney injury (AKI) remains a major global public health concern due to its high morbidity and mortality. The progression from AKI to chronic kidney disease (CKD) makes it a scientific problem to be solved. However, it is with lack of effective treatments. Summary: Both innate and adaptive immune systems participate in the inflammatory process during AKI, and excessive or dysregulated immune responses play a pathogenic role in renal fibrosis, which is an important hallmark of CKD. Studies on the pathogenesis of AKI and CKD have clarified that renal injury induces the production of various chemokines by renal parenchyma cells or resident immune cells, which recruits multiple-subtype lymphocytes in circulation. Some infiltrated lymphocytes exacerbate injury by proinflammatory cytokine production, cytotoxicity, and interaction with renal resident cells, which constructs the inflammatory environment and induces further injury, even death of renal parenchyma cells. Others promote tissue repair by producing protective cytokines. In this review, we outline the diversity of these lymphocytes and their mechanisms to regulate the whole pathogenic stages of AKI and CKD; discuss the chronological responses and the plasticity of lymphocytes related to AKI and CKD progression; and introduce the potential therapies targeting lymphocytes of AKI and CKD, including the interventions of chemokines, cytokines, and lymphocyte frequency regulation in vivo , adaptive transfer of ex-expanded lymphocytes, and the treatments of gut microbiota or metabolite regulations based on gut-kidney axis. Key Message: In the process of AKI and CKD, T helper (Th) cells, innate, and innate-like lymphocytes exert mainly pathogenic roles, while double-negative T (DNT) cells and regulatory T cells (Tregs) are confirmed to be protective. Understanding the mechanisms by which lymphocytes mediate renal injury and renal fibrosis is necessary to promote the development of specific therapeutic strategies to protect from AKI and prevent the progression of CKD.

Pathogenesis and treatment progress in chronic kidney disease after acute kidney injury

Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease

Pathogenesis of Chronic Allograft Dysfunction Progress to Renal Fibrosis.

Pathophysiology and Therapeutic Targets

Mechanism and prevention of the transformation from AKI to CKD

The pathological role of damaged organelles in renal tubular epithelial cells in the progression of acute kidney injury

AKI: an increasingly recognized risk factor for CKD development and progression

Macrophages in Renal Injury, Repair, Fibrosis Following Acute Kidney Injury and Targeted Therapy

Transition from Acute Kidney Injury to Chronic Kidney Disease: Mechanisms, Models, and Biomarkers

How Acute Kidney Injury Contributes to Renal Fibrosis.

Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical prospects.

Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease

Pathway from Acute Kidney Injury to Chronic Kidney Disease: Molecules Involved in Renal Fibrosis

Cellular senescence and acute kidney injury

Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms

Potential targeted therapy and diagnosis based on novel insight into growth factors, receptors, and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression

Targeting the progression of chronic kidney disease

Epigenetic Modification Drives Acute Kidney Injury-to-Chronic Kidney Disease Progression

Lymphocytes: Versatile Participants in Acute Kidney Injury and Progression to Chronic Kidney Disease

New therapeutic targets in chronic kidney disease progression and renal fibrosis